Asthma Comparative Effectiveness Study (Asthma CER)

AstraZeneca

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT01623544

RWE-000015

Details and patient eligibility

About

The objective of this study is to compare the real-world effectiveness of BFC and FSC in asthma patients new to ICS/LABA combination therapy in a population of U.S. health plan enrollees.

Full description

A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients

Enrollment: 6,086 patients

Sex: All

Ages: 12 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Continuous health plan enrollment for 12 months before and after index Rx
• At least two prescription fills for BFC or FSC within 12 months
• Asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription

Exclusion criteria

• Evidence of COPD
• Claims diagnosis of any of inflammatory diseases or cancer
• Presence of Rx for more than one type of ICS/LABA combination on index date
• Chronic steroid use or Xolair use prior to ICS/LABA index treatment

Trial design

6,086 participants in 2 patient groups

Symbicort

Description:

BFC patients new to ICS/LABA combination therapy

Advair

Description:

FSC patients new to ICS/LABA combination therapy